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Abstract
Introduction:	Chemical	pleurodesis	is	an	accepted	palliative	therapy	for	patients	with	recurrent	and	symptomatic	pleural	effusion.	The	
aim	of	the	study	is	to	present	our	own	experiences	with	a	less	invasive	variant	of	this	procedure	performed	with	talc	slurry	administered	
via	a	chest	tube	under	local	anaesthesia.	Available	medical	literature	in	Polish	does	not	contain	information	about	this	type	of	pleurodesis.
Material and methods:	During	2005–2011	in	the	Pulmonology	and	Respiratory	Rehabilitation	Department	we	hospitalized	and	
diagnosed	162	patients	with	pleural	fluid.	Pleurodesis	was	performed	in	24	patients	(14.8%)	with	persistent	pleural	fluid.	In	this	
article	we	present	retrospective	analysis	of	safety,	efficacy	of	treatment	and	patients’	survival	time.	We	also	provide	detailed	
information	about	 this	 type	of	pleurodesis:	clinical	 theory,	 indications,	contraindications,	patient’s	preparation,	description	of	
procedure	with	our	modifications	and	use	of	chest	X-ray	and	transthoracic	ultrasound.
Results:	The	procedure	was	effective	in	20	cases,	partially	effective	in	3	cases	and	ineffective	in	one	case.	In-hospital	mortality	
was	4.2%	(one	case).	We	frequently	observed	mild	fever	and	local	pain.	Median	hospitalization	was	9	days.	Median	survival	time	
was	32	days,	whereas	in	the	group	of	still	living	patients	it	was	96	days.
Conclusions:	Talc	slurry	pleurodesis	with	adequate	patient	preselection	is	a	relatively	effective	and	safe	procedure.	The	procedure	
can	be	performed	in	a	non-surgical	pulmonology	unit.
Key words:	pleurodesis,	talc	slurry,	lung	cancer,	pleural	effusion
Pneumonol. Alergol. Pol. 2013; 81: 439–447 
Streszczenie
Wstęp:	Pleurodeza	chemiczna	jest	uznaną	metodą	paliatywnego	leczenia	uporczywych	wysięków	gromadzących	się	w	jamach	
opłucnowych.	Celem	pracy	jest	prezentacja	własnych	doświadczeń	z	mniej	obciążającą	formą	zabiegu	wykonywanego	za	pomo-
cą	zawiesiny	talku	medycznego	podawanego	przez	dren,	wymagającego	jedynie	znieczulenia	miejscowego.	W	piśmiennictwie	
polskojęzycznym	brak	pozycji	opisujących	doświadczenia	z	wyżej	wymienioną	modyfikacją	pleurodezy.	
Materiał i metody:	W	latach	2005–2011	hospitalizowano	na	Oddziale	Pulmonologii	i	Rehabilitacji	Oddechowej	Wojewódzkiego	
Szpitala	Chorób	Płuc	w	Wodzisławiu	Śląskim	162	chorych	u	których	rozpoznano	płyn	w	jamie	opłucnej.	Ze	względu	na	uporczywe	
gromadzenie	się	płynu	u	24	(14,8%)	z	nich	wykonano	pleurodezę.	Praca	zawiera	retrospektywną	analizę	wykonanych	zabiegów	
z	uwzględnieniem	bezpieczeństwa,	skuteczności	i	przeżywalności	pacjentów,	podstawy	teoretyczne,	wskazania,	przeciwwska-
zania,	zasady	przygotowania	pacjenta,	przebieg,	ocenę	skuteczności,	własne	modyfikacje	zabiegu	oraz	ocenę	wartości	badania	
radiologicznego	i	ultrasonograficznego	klatki	piersiowej.
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Wyniki:	Zabieg	okazał	się	skuteczny	u	20	chorych,	częściowo	u	3,	u	jednego	chorego	stwierdzono	brak	skuteczności,	a	u	jednego	
zgon	wewnątrzszpitalny.	Najczęstszymi	powikłaniami	były	ból	i	gorączka	o	niewielkim	nasileniu.	Mediana	hospitalizacji	wynosiła	
9	dni.	Mediana	czasu	przeżycia	osób	zmarłych	wyniosła	32	dni,	a	wśród	nadal	żyjących	chorych	96	dni.
Wnioski:	 Pleurodeza	 zawiesiną	 talku	 przez	 dren	 z	 odpowiednią	 selekcją	 pacjentów	 jest	 zabiegiem	 stosunkowo	 skutecznym	 
i	bezpiecznym.	Zabieg	jest	możliwy	do	wykonania	w	warunkach	oddziału	pulmonologicznego.
Słowa kluczowe:	pleurodeza,	zawiesina	talku,	rak	płuca,	wysięk	opłucnowy
Pneumonol. Alergol. Pol. 2013; 81: 439–447 
Introduction
Under physiological conditions the pleural 
cavity is filled with approximately 10–20 ml of 
fluid, which ensures sliding during the change of 
volume and position of the lung [1]. Under patho-
logic conditions it becomes ‘a third space’, which 
enables accumulation of transudates, exudates, 
blood, air or lymph. Due to the limited volume 
of the chest, a great amount of fluid or gas in the 
pleural cavity causes symptoms connected with 
restrictive ventilatory disorders and compression 
of the right cardiac cavities and big venous ves-
sels, which may result in patient death. A specific 
reaction causing the pleural laminae to enter an 
inflammatory state is agglutination, as also hap-
pens in another serous membrane covered with 
mesothelial tissue — the peritoneum. This leads 
to a beneficial limitation of infection and favours 
a spontaneous recovery, which can often be ob-
served in tuberculous pleural effusion. Excessive 
intensification of fibrosis of the obliterated pleura 
may lead to fibrothorax, observed after exudates, 
pleural hematoma and asbestosis. Deliberately 
triggered adhesion of the pleural laminae is 
known as pleurodesis (obliteration of the pleural 
cavity). This is to eliminate the potential space 
in which fluid or air may be stored, and it was 
described for the first time in 1935 by Bethune 
[2]. In the beginning only endoscopic talc poudra-
ge performed under sight control on a partially 
collapsed lung was used. An unquestionable 
advantage of this method, which is the thoracic 
surgeons’ domain, is the possibility of one-time 
taking up of histopathological material; however, 
one disadvantage is its invasiveness, i.e. the need 
for general anaesthesia or deep sedation, selective 
intubation or ventilation. An even more effecti-
ve method, but also invasive, is pleurectomy or 
mechanical rubbing of the pleura until drops of 
blood appear — the two procedures are possible 
during classic thoracotomy. In 1994 Lisa Kennedy 
et al. published the results of administering talc 
slurry via chest tube, used also as treatment for 
recurrent non-neoplastic fluids (bronchopleural 
fistulas, fluid in chronic constrictive pericarditis); 
additionally, she observed in 8 out of 58 patients 
that large doses of glycocorticosteroids did not 
influence the results of the procedure [3]. Cont-
rary to fibrothorax, pleurodesis causes only small 
ventilatory restriction as adhesion of the pleural 
laminae is performed without intense fibrosis. For 
example, mean total lung capacity (TLC), assessed 
22–35 years after pleurodesis due to pneumotho-
rax, reached 89% of predicted values and only 
in one case was it lowered by up to 58% of the 
predicted value [4]. Thirty different obliterating 
agents have been described, but the most effective 
and the most frequently used remains medical 
talc. The mechanics of pleurodesis is not fully 
known. Research has shown that talc phagocyto-
sis activates fibroblasts and coagulation cascade 
through neutrophilic granulocytes. Examination 
of the pleural fluid after talc insufflation in hu-
mans and animals confirms a transitory increase 
in the number of neutrophilic granulocytes, 
D-dimers, interleukin 8, vascular endothelial 
growth factor (VEGF), transforming growth factor 
b1 (TGF-b1) and endostatin. Concentrations of 
these markers in the pleural fluid measured post 
factum are predictors of the procedure’s effecti-
veness [5–7]. Recognized predictive factors of an 
effective procedure include the biggest surface of 
the pleura covered with undamaged mesothelial 
tissue, regular or increased fluid pH, and the 
possibility of approachment of the pleural lami-
nae, i.e. so-called expanded lung [8]. It happens 
this way because regular mesothelial cells are 
responsible for the creation of the inflammatory 
state and adhesions. Therefore, in pleurodesis 
performed because of pneumothorax, a smaller 
quantity of talc (3–4 g) is put on the unchanged 
pleura, causing pain and fever, than in patients 
with pleural exudate in the course of the pleura 
affected by neoplasm (5 g) [9]. Keeping a chest 
tube in the pleural cavity for a long time may 
cause spontaneous pleurodesis in the pathologi-
cally changed pleura. Such a fact was described in 
64% of the 109 outpatients treated with tunnelled 
pleural catheter (TPC, Pleurx®, Carefusion), from 
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which a patient on his own takes the fluid up to 
a vacuum container [10, 11].
Material and methods
In the years 2005–2011, among patients 
hospitalized in the Department of Pulmonology 
and Respiratory Rehabilitation of the Provincial 
Hospital of Lung Diseases in Wodzisław Śląski, 
there were 162 patients with diagnosed pleural 
effusion. The majority of them were patients 
with reactive fluid, self-limiting or responding to 
treatment in the course of infection, pulmonary 
thromboembolism, after injury, circulatory insuf-
ficiency or pancreatic cyst. As a criterion for pleu-
rodesis eligibility, recurrent pleural fluid in pa-
tients with several months survival was accepted. 
In this way a group of 24 (14.8%) patients, to 
whom the procedure was proposed and who 
gave consent to it, was selected. The following 
factors were assumed as contraindication against 
pleurodesis: lack of the patient’s consent and co-
operation, poor general condition, trapped lung 
(discussed later), active infection of the pleura 
or the lung, slow accumulation of the fluid with 
decompressions once a month or, more rarely, 
haemorrhagic diathesis and potential possibility 
of achieving rapid improvement due to other 
methods, e.g. beginning first-line chemotherapy 
for small cell lung cancer. An additional contra-
indication against pleurodesis seems to be the 
presence of thick fluid that is difficult to mix with 
talc slurry, as in the case of pleural amyloidosis, 
discussed later.
The following procedure scheme was used:
1. Selection and preparation of the patients: 
After admission to the Department, image 
and laboratory examinations were carried 
out. Following an accessible explanation, the 
patients gave consent to the procedure. Before 
drainage was inserted we did not take all of 
the fluid — leaving at least 500 ml, i.e. ≈ 6 cm 
on ultrasonography in horizontal measure-
ment in sedentary patients, which increased 
the safety of the procedure. The dose of low- 
-molecular-weight heparin was omitted on 
the day of the procedure, oral anticoagulants 
were omitted for the precedent 3 days, and the 
application of acetylsalicylic acid remained 
unchanged. Glycocorticosteroids administe-
red in medium and large doses, i.e. over 10 mg 
of prednisolone per day, were discontinued. 
Patients had intravenous insertion of a needle, 
arterial blood pressure measured and were 
then recommended to have a light but filling 
meal in order to reduce the risk of vasovagal 
syncope. Thirty minutes before the procedure 
the patients were given subcutaneously 5 mg 
of morphine sulphate and intravenously 2500 
mg of metamizole (1 ampule).
2. Insertion of pleural drainage: The procedure 
took place in the ultrasonography room with 
an ultrasonograph controlling the sedentary 
patient. The following equipment was pre-
pared: sterile drape, vice, scalpel, Kocher’s 
forceps and scissors, non-absorbable surgical 
thread 2–0 with a cutting needle (2 pcs), ru-
bber tunica of the tube’s ending from sterile 
dropper, leader for inserting drain, 10 ml of 
2% lignocaine to anesthetize the skin, pleu-
ral drain 20F with trocar, resuscitation kit, 
disinfectants, sterile gauze swabs and gloves, 
and disposable waterproof apron. Mid or back 
axillary line forward from the widest back 
muscle border was usually chosen for dra-
inage. Intercostal space for inserting the chest 
tube was chosen based on the quantity of fluid 
visible during ultrasonography in order to mi-
nimize rubbing organs against the chest tube 
and the consequent pain — after fluid remo-
val the lower border of the lung was lowered 
and the phrenic dome was made higher; the 
second intercostal space above diaphragm 
was usually chosen for approximately 1000 ml 
of fluid. The place to insert a chest tube 
first underwent infiltration anaesthesia with 
lignocaine (consecutively skin, intercostal 
space muscles under the rib’s border forward 
and backward, and the parietal pleura, until 
the fluid was aspirated). After the loss of 
pain sensitivity, usually with retained touch 
sensibility, the skin was incised with scalpel 
at the length of the chest tube circumference, 
then the leader with the chest tube in the 
groove was inserted into the opening. Slight 
rotary motion of the leader was used to help 
cut the tissues until the pleura was punctu-
red, which was recognized by a decrease in 
resistance and the appearance of fluid in the 
groove (Fig. 1). Consecutively, the chest tube 
with 4 cut-out lateral openings through the 
guide’s groove was inserted, then the leader 
was removed, and the chest tube ending was 
placed in the posterior costo-diaphragma-
tic recess under ultrasonograph control at 
a depth of approximately 16 cm, i.e. 10 cm 
from the last opening. Then the trocar was 
removed and two vertical mattress sutures 
and one horizontal mattress delayed suture 
were laid around the tube.
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3. Radiological control in posteroanterior (PA) 
and lateral projection after complete fluid 
evacuation (Figs 2–4).
4. Submerged passive drainage with evaluation 
of ultrasonography of the pleura after 24 ho-
urs. If the amount of drained fluid dropped 
below 100–150 ml during 24 hours, pleuro-
desis was to be performed.
5. Talc poudrage of the pleura. Morphine sulpha-
te was administered subcutaneously, metami-
zole — intravenously, as for drainage, then 10 
ml of 2% lignocaine — intrapleurally, with 
subsequent changes of body position: prone, 
supine, on the left side and right side with the 
hips raised and whilst taking deep breaths. 
Subsequently, 5 g of sterile talc (COEL, Kra-
ków) suspended directly before administration 
in 50 ml of 0.9% solution NaCl, heated to body 
temperature, was administered intrapleurally, 
and then 10 ml of warm solution of 0.9% of 
NaCl was administered so that the slurry left 
the chest tube completely. The chest tube was 
closed for 2 hours and then again deep breaths 
and changing of body positions took place 
similarly as during anaesthesia of the pleura, 
with repetition at least once after 30 minutes. 
After 2 hours the patient was connected to 
submerged passive drainage.
6. Evaluation of the amount of drained fluid 
after 24 hours: It was usually close to zero, 
which meant good effectiveness of the pro-
cedure. In such a situation after ultrasono-
graphic and radiological control the chest 
tube was removed with clamping of the de-
layed suture. If the fluid continued to drain, 
further observation for 24 hours was applied 
and possible second pleurodesis performed.
The effectiveness of the pleurodesis was eva-
luated on the grounds of a radiogram performed 
Figure 1. Insertion	of	a	chest	tube	to	the	pleura	with	the	help	of	a	guide Figure 2. P.A.	 male	 65	 years	 of	 age,	 mesothelioma	 of	 the	 pleura,	
radiological	control	of	the	position	of	the	chest	tube
Figure 3.	P.M.	male	86	years	of	age,		persistent	exudate	of	unknown	
orygin	with	symptomatic	treatment,	radiological	control	of	the	position	
of	the	chest	tube
Figure 4.	 U.G.	 male	 70	 years	 of	 age,	 mesothelioma	 of	 the	 pleura,	
radiological	control	of	the	position	of	the	chest	tube
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after the insertion of the chest tube and fluid eva-
cuation. In some patients fluid evacuation after 
drainage insertion and before pleurodesis was se-
parated by a 1.5–3-hour break due to fluid drainage 
in the amount over 1200–2000 ml. The capacity at 
which fluid evacuation should be stopped in order 
to avoid pulmonary oedema after expansion was 
defined for each patient individually, taking into 
consideration their height, body mass, general con-
dition and appearance of cough and pleurodynia. 
The effectiveness of the pleurodesis itself 
was evaluated on the grounds of radiogram and 
ultrasonography made after chest tube removal. 
The following interpretation of the procedure’s 
effectiveness was applied:
—  good: chest radiogram in PA view close to 
normal, separation of the pleural laminae 
through the fluid in ultrasonography in 
posterior costo-diaphragmatic recess or the 
widest place close to 3 cm;
—  partial: smaller, self-limiting or slower fluid 
accumulation than before the procedure;
—  lack: without any influence on fluid accumu-
lation.
Distant control of patients who were to be 
managed in other oncological centres was not 
planned, but patients were to notify about recur-
rence of ailments connected with pleural exudate. 
The remaining patients with primary lung cancer 
and mesothelioma of the pleura were still un-
dergoing casual or symptomatic treatment in the 
local Department and Outpatient Clinic and were 
controlled ultrasonographically during subsequ-
ent cycles of cytostatic treatment, radiotherapy 
and post-hospital visits.
Information about the patients’ date of death 
was obtained by phone based on contact with re-
latives from medical documentation; additionally, 
the question of whether the problem with fluid 
in the pleural cavity recurred before the patient’s 
death was asked. The above-mentioned informa-
tion was obtained on 25 January 2012, and this 
date was accepted for calculation of survival time 
of still living patients. When, as in 8 cases, there 
was no available phone number, information 
about the date of death was obtained via written 
application for personal data disclosure to the 
Offices of Civil Affairs in City Halls of Jastrzębie 
Zdrój, Rybnik, Pszów and Żory.
Results
All 24 patients who underwent the procedu-
re met the criteria of exudate fluid (the median 
LDH concentration in fluid 789 IU/l, the median 
protein concentration 5.0 g/l). Neoplastic backgro-
und in the fluid was found in 23 (96%) patients; 
cytological or histopathological tests confirmed 
neoplasm in 21 patients. Among the recognized 
neoplasms the most frequent was mesothelioma 
of the pleura (7 patients), lung cancer (6 patients, 
including adenocarcinoma — 3 patients, carcino-
mas: squamous, small cell, non-small cell, not dif-
ferentiated — each type recognized in 1 patient), 
breast cancer (4 patients), malignant melanoma of 
the skin (2 patients), 1 patient with carcinoma of 
the kidney and 1 patient with papillary carcinoma 
of cancer of unknow origin. The median age of 
patients was 67 years, and the median volume of 
fluid evacuated before the procedure was 3975 ml 
(range 1500–12000 ml). Men constituted 59% of 
all patients. Right- and left-sided exudates amo-
unted to 50% each (Table 1).
The median hospitalization was 9 days (ran-
ge 3–42 days). Hospitalization of patients was 
longer due to their general condition, which 
did not allow the procedure to be performed, or 
was caused by waiting for results of cytostatic 
treatment that would cause them to resign from 
pleurodesis. In the case of planned admission 
for pleurodesis, hospitalization for the majority 
of patients did not exceed 4 days. The effective-
ness of the procedure was evaluated as good in 20 
patients, as partial in 3 patients, and as lacking 
effectiveness in one patient. One death in hospital 
occurred after 3 days from the procedure, it was 
not connected directly with the condition of the 
patient’s respiratory system. The median survival 
time from the day of procedure among the patients 
who died was 32 days (range 3–292 days), and 
among living patients it is 96 days (range 78–629 
days). The longest survival time among patients 
who died was noted in one man (P.A.) at 65 years, 
with mesothelioma of the pleura treated with 
2 cycles of pemetrexed with cisplatin and witho-
ut inhibition of fluid production, and in another 
man (C.I.) it was 44 years, with dissemination of 
malignant melanoma of the skin, who died after 
277 days from the procedure due to brain meta-
stases. Among the living patients 629 days passed 
from the procedure in one man (U.W.), who was 68 
years old, with mesothelioma of the pleura and had 
pleurodesis due to carcinoma progression despite 
the administration of two cycles of chemotherapy 
with pemetrexed and cisplatin. Currently the 
patient is being prepared for pleurodesis of the 
opposite pleural cavity because of chylothorax 
with progressing cachexy. On the evening of the 
procedure a slight fever and pain was noted in 
fewer than half of the patients (Table 2). 
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Discussion
Pleurodesis of the pleural cavity results in 
a significant improvement in the patient’s life qu-
ality, especially in cases of progressing neoplastic 
disease. Fluid in the pleural cavity in the amount 
which gives the patient the feeling of dyspnoea 
causes additional psychological discomfort and 
anxiety as, in popular opinion, lung cancer is asso-
ciated with death from suffocation. Additionally, 
the insufficient number of physicians in Poland, 
difficulties in consulting a medical specialist, 
and busy working times in outpatient clinics and 
home hospices despite the best intentions of the 
medical staff, do not favour care for patients who 
need decompressions at times that are difficult to 
predict. Repeated fluid evacuation in neoplastic 
disease with intense catabolism deepens protein 
deficiency — theoretically 2 punctures, each of 
1500 ml of exudate of protein concentration close 
to the plasma, deprive the patient of the same 
amount of protein as is contained in his/her whole 
plasma, assuming that blood volume constitutes 
7% of body mass and plasma constitutes 60% of 
blood volume. Such protein, especially albumin, 
has to be synthesized again in the liver.
After pleurodesis we observed one death, 
which happened during the third day after the 
procedure. It was the patient S.J., 59 years of age, 
who was treated for chronic schizophrenia. The 
patient was diagnosed with non-small cell cancer 
of the right lung. First he was ordered to undergo 
irradiation of neoplastic metastasis in the eighth 
thoracic vertebral body of spine. During ambula-
tory radiotherapy rapid renewal of fluid, which 
needed pleurodesis, was observed. 24 hours after 
the partially effective procedure (300 ml of fluid 
in adhesions), despite the lack of fever, the patient 
started to be delirious (which required additional 
administration of sedative) and was able only to 
maintain poor logical contact. Neither circulatory 
nor respiratory insufficiency were observed, and 
the patient died suddenly during the night three 
days after the procedure. Autopsy was abandoned 
upon request of the patient’s family. It is known 
that talc after intrapleural administration in rats 
in doses corresponding to 2.5 g and 5.0 g for 
a 70 kg man accumulates in internal organs, in 
greater concentration in the brain than in kidney 
or spleen (a test with the use of traditional non-ca-
Table 1. Characteristic of the study group
Age	(years) 67	(43–83)
Sex	(F/M) 10/14	(58%	vs.	42%)
Time	from	diagnosis	of	the	disease	to	pleurodesis	(months) 3	(0–72)
Patients	with	exudate	/	transudate 24/0
Fluid	evacuation	before	pleurodesis	[ml] 3975	(1500–12000)
Causes	of	exudate Adenocarcinoma	of	the	lung 3
Malignant	mesothelioma	of	the	pleura 7
Breast	cancer 4
Malignant	melanoma	of	the	skin 2
Papillary	carcinoma	FPI 1
Squamous	cell	carcinoma	of	the	lung 1
Non-small	cell	lung	cancer	NOS 1
Small	cell	lung	cancer 1
Carcinoma	of	the	kidney 1
Amyloidosis	of	the	pleura 1
Lack	of	diagnosis 1
Data	are	presented	in	the	form	of	median	with	the	range	in	brackets 
NOS	—	not	otherwise	specified;	FPI	—	focus	primarius	ignotus 
Table 2 . Effectiveness and safety of talc slurry pleurode-
sis via chest tube
Time	of	hospitalization	(days) 9	(3–42)
Living	patients/deceased,	who	underwent	pleurodesis 19/5
Survival	time	after	pleurodesis	in	patients	who	died	
(days)
32 
(4–292)
Evaluation	of	pleurodesis	effectiveness	 
(good/partial/lack)
21/2/1
Evaluation	of	safety	(lack	of	symptoms	or	mild	symp-
toms	after	pleurodesis/serious	symptoms/death)	
22	/1/1
Data	are	presented	in	the	form	of	median	(range)
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librated talc particles) [12]. Whereas Fraticelli et 
al. repeated the experiment on rats with calibra-
ted talc and discovered its significantly smaller 
distribution to organs from outside the chest 
[13]. It is possible that systemic distribution of 
talc could have contributed to deterioration of 
the patient’s mental state, and in the case of the 
repeated complication in the future psychiatric 
disorders or neurological defects could be a 
new, thus far unknown contraindication against 
pleurodesis with traditional talc. The talc that 
is used in our Department has particles of size 
below 75 μm, it is portioned and sterilized with 
dry and hot air, which is permitted in the guide-
lines. Guidelines permitted optionally steriliza-
tion with use of ethylene oxide and gamma rays, 
comparing the cost with traditional sterilization 
[14]. The norm for microbiological purity before 
sterilization, i.e. < 500 CFU/g, is also met — the 
producer of the talc gives < 100 CFU/g. Talc still 
remains the most effective, least expensive and 
well-tried agent for pleurodesis. Nevertheless, it 
has been attributed to at least 32 cases of acute 
respiratory failure syndrome [15], which may 
be also associated with systemic activation of 
the coagulation system [16].
The procedure was ineffective only in the 
patient — E.R, 68 years of age, who was under-
going long-standing haemodialysis due to end 
stage renal disease in the course of rheumatoid 
arthritis with epilepsy and heart disease. The 
presence of a thick, protein rich fluid with LDH 
1541 IU/l and negative rheumatoid factor was 
discovered in the patient’s left, and recently also 
right, pleural cavity and in the pericardium, 
which was diagnosed as pleural amyloidosis. In 
macroscopic testing the fluid was characterized 
by pronounced stickiness — it was flowing to the 
aspirator’s container, without dividing into drops 
or creating froth, in which it resembled syrup. The 
patient was disqualified from thoracic surgery 
(pleurostomy with local anaesthesia). Although in 
the chest radiogram in posteroanterior projection 
a lack of total lung expansion after thoracocentesis 
was observed, pleurodesis was performed due to 
recurrent effusion but turned out to be ineffective 
probably because of immiscibility of talc slurry 
and the thick fluid. After the procedure some com-
plications developed: pleural haematoma, which 
needed red bood cells tranfusion, appeared — to 
which uremic haemorrhagic diathesis contributed 
with more than two times prolonged prothrombin 
and activated partial thromboplastin time. The 
patient still has the pleural fluid twice a month 
it is removed by pleurocenthesis.
After observations we assumed that during 
thoracocentesis in order to force evacuation of the 
fluid the trapped lung needs hypotension greater 
than — 0.2 bar on the aspirator’s manometer. It 
should be emphasized that the pressure on the 
aspirator’s manometer does not correspond to 
intrapulmonary pressure because it does not 
take into account the difference between levels, 
the drop in pressure in the hose, and above all 
in the 1.2 × 40 mm needle used routinely for 
thoracocentesis. During removal via chest tube 
the above-mentioned resistance does not occur, 
the aspirator is not turned on, and additionally, 
too rapid removal of the fluid has to be inhibited, 
usually by partial bending of the chest tube. In 
the guidelines of the American Thoracic Society 
failure of complete lung expansion is defined by 
the value of difficult to measure intrapulmonary 
pressure –10 cm H2O at the beginning of tho-
racocentesis or –20 cm H2O after evacuation of 
1 litre of exudate [14]. This logical contraindica-
tion, i.e. lack of possibility of obliteration of the 
pleural cavity, may result from obstruction of the 
main bronchus or extensive pleural infiltration, 
and is observed on chest radiographs as a lack of 
contralateral mediastinal shift [14].
Using a guide for the chest tube has many 
advantages: minimal tissue injury, very good 
tightness of the chest tube, easy perforation of 
the hardened pleura, a short time of manipula-
tion (less than 10 seconds), and easy cleaning 
and sterilization. Insertion of the chest tube in 
a traditional way, e.g. with the help of scissors, 
especially in obese patients, results in poorer 
tightness but lasts significantly longer (Fig. 5).
Figure 5. A guide which serves to insert a chest tube to the pleura
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It should be emphasized that in our research 
pleurodesis was effective with passive submerged 
drainage, without recommended active drainage 
under suction 20 cm H2O [3, 14, 16].
Some patients with fluid in the pleura have 
psychogenic dyspnoea and they request frequent 
thoracocentesis and numerous visits in hospital. 
It is typical that their dyspnoea abates directly 
after insertion of a needle into the pleura and the 
removal of just a minimal quantity of the fluid 
(own observation of several patients). The ap-
propriate treatment is drugs — benzodiazepines 
and weak neuroleptic and anti-depressive drugs, 
which are usually effective during monotherapy, 
and give an accessible explanation of the problem 
by the physician. In our opinion these are patients 
who cannot manage neoplastic disease and who 
function using patterns of thought such as ‘I have 
fluid — I have cancer, I do not have fluid — cancer 
withdrew, it is under control’.
Due to the retrospective character of this pa-
per, a lack of remote control, and evaluation of the 
influence on life quality and interference of sequ-
entially used cytostatic treatment or radiotherapy, 
the assessment of the influence of the procedure 
on patients’ length of life in such a small group 
seems to be pointless. Another disadvantage of 
retrospective character of this paper is the means 
of evaluation of pleurodesis effectiveness, which 
consists in noting the lack of exudate or its failure 
to accrete in adhesions during the 24–48 hours 
after the procedure. With personnel shortages and 
remote dates of control in the Outpatient Clinic, 
this way of doing it is logistically sufficient as pa-
tients with delayed ineffectiveness of pleurodesis 
will report to the Admission Room with intensive 
dyspnoea, which was also recommended during 
discharge from hospital. A well-planned retro-
spective study would need scheduled controls, 
e.g. 30, 90 and 180 days after the procedure, with 
radiogram and standardized ultrasonogram of the 
chest. An example of a Polish prospective study 
concerning the comparison of videothoracoscopic 
pleurodesis using talc and doxycycline is the 
study carried out by Kudżał et al., in which the 
authors used, similarly as we did, a simplified 
three-phase means of evaluation of effectivenes 
the procedure [17].
 Conclusions
Although pleurodesis does not belong to 
symptomatic treatment of the disease, it relieves 
the patient of the problem and it was always seen 
by patients and their families as positive and 
useful. It is possible to perform the procedure in 
a pulmonological departments as ours, without 
experience or equipment for medical thoraco-
scopy, which in Poland is performed only in 
a few non-operative departments. In comparison 
to directing the patient to Thoracic Surgery De-
partment, talc slurry pleurodesis via chest tube 
allows the patient to avoid travelling, subsequent 
hospitalization, and general anaesthesia and 
offers a near date for the procedure — even the 
following day after making the decision. Medical 
staff save the time that they would spend on 
arrangements concerning directing the patient. 
If the procedure starts in the first half of the week, 
the patient is discharged from hospital without 
chest tube on Thursday or Friday. Based on our 
experience, we think that talc slurry pleurodesis 
via chest tube is a safe and useful procedure 
worth spreading. Pulmonological departments in 
multidisciplinary hospitals may count on gene-
ral surgeons’ support while inserting drainage, 
and pulmonologists will be left with pleurode-
sis, which does not differ from the procedure of 
washing the pleura.
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